CABA treatment for end-stage liver disease with inflammation
This study tests a treatment called CABA for people with advanced liver disease and inflammation. It aims to see if CABA can help improve liver function and reduce inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have end-stage liver disease such as cirrhosis with complications, chronic liver failure, or acute-on-chronic liver failure.
- You have signs of inflammation, for example high levels of certain blood tests (PCT, CRP, IL-6, or IL-8).
- You do not have liver cancer or other tumors, HIV, or other immune problems.
- You are not pregnant or breastfeeding.
- You are willing to follow the study schedule and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two treatments for advanced liver cancer (hepatocellular carcinoma): a bile acid supplement called tauroursodeoxycholic acid plus an immunotherapy drug (a PD-1/PD-L1 inhibitor) that helps your immune system fight the cancer. The goal is to see if this combination is safe and effective in people who have not yet had any whole-body cancer treatment.
This trial tests two different blood-filtering treatments for people with severe liver failure who are waiting for or unable to receive a liver transplant. It aims to see how these treatments affect blood clotting, inflammation, and organ function.
This trial tests a new drug called AS1501 for people with acute-on-chronic liver failure (a sudden worsening of chronic liver disease). It aims to see if the drug can help improve liver function and reduce the need for a liver transplant. You may be eligible if you are in the early or middle stage of this condition and have a specific blood marker (high TRAIL level).
This trial tests an experimental drug for people with severe alcoholic hepatitis that did not improve with steroids. Participants should have a moderate level of organ failure, but not require a breathing tube or kidney dialysis.
This trial studies whether the ALSS treatment is safe and effective for people with hepatitis B-related hepatocellular carcinoma who recently received immune checkpoint inhibitors. It may help improve outcomes for certain liver-related complications after immunotherapy, based on how their liver tests look.
This is a study that collects real-world information about people with liver failure or “pre-liver failure.” It aims to help doctors choose the best management approach for patients like you and improve care over time.
Hear when a new To Evaluate the Clinical Efficacy and Safety of the New ALSS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.